TLSI
TriSalus Life Sciences Inc

272
Mkt Cap
$236.37M
Volume
37,926.00
52W High
$5.88
52W Low
$3.42
PE Ratio
-4.02
TLSI Fundamentals
Price
$4.74
Prev Close
$4.67
Open
$4.62
50D MA
$4.84
Beta
0.39
Avg. Volume
122,343.95
EPS (Annual)
-$1.31
P/B
-9.27
Rev/Employee
$267,554.54
Loading...
Loading...
News
all
press releases
TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
TriSalus Life Sciences to Participate in Upcoming September Investor Conferences
TriSalus Life Sciences Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients...
Business Wire·2mo ago
News Placeholder
TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of -22.73% and +5.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
Myomo (MYO) delivered earnings and revenue surprises of 0.00% and +6.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Zimmer Biomet (ZBH) Beats Q2 Earnings and Revenue Estimates
Zimmer (ZBH) delivered earnings and revenue surprises of +4.55% and +1.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates
Zacks·6mo ago
News Placeholder
OrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised)
Zacks·6mo ago
News Placeholder
TriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays Pessimistic
The company reaffirmed its previous guidance for 2025 and said it expects sales growth of over 50% and its gross margin to exceed 87%, higher than the 86% reported for 2024.
Stocktwits·7mo ago
News Placeholder
TriSalus Life Sciences Announces Key Appointments to Board of Directors
TriSalus Life Sciences Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with...
Business Wire·9mo ago
News Placeholder
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
TriSalus Life Sciences Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with...
Business Wire·9mo ago

Latest TLSI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.